318 related articles for article (PubMed ID: 26355862)
21. [Utterly unanticipated findings].
Jordan B
Med Sci (Paris); 2015 May; 31(5):567-8. PubMed ID: 26059309
[TBL] [Abstract][Full Text] [Related]
22. [Clinical application of noninvasive prenatal diagnosis using cell free fetal DNA in maternal plasma].
Hou QF; Wu D; Chu Y; Kang B; Liao SX; Yang YL; Zhang CY; Zhang JX; Wu G
Zhonghua Fu Chan Ke Za Zhi; 2012 Nov; 47(11):813-7. PubMed ID: 23302120
[TBL] [Abstract][Full Text] [Related]
23. Modifying Risk of Aneuploidy with a Positive Cell-Free Fetal DNA Result.
Long AA; Abuhamad AZ; Warsof SL
Clin Lab Med; 2016 Jun; 36(2):249-59. PubMed ID: 27235910
[TBL] [Abstract][Full Text] [Related]
24. The consequences of implementing non-invasive prenatal testing in Dutch national health care: a cost-effectiveness analysis.
Beulen L; Grutters JP; Faas BH; Feenstra I; van Vugt JM; Bekker MN
Eur J Obstet Gynecol Reprod Biol; 2014 Nov; 182():53-61. PubMed ID: 25238658
[TBL] [Abstract][Full Text] [Related]
25. The impact of noninvasive prenatal testing on the practice of maternal-fetal medicine.
Friel LA; Czerwinski JL; Singletary CN
Am J Perinatol; 2014 Oct; 31(9):759-64. PubMed ID: 24338115
[TBL] [Abstract][Full Text] [Related]
26. Prenatal cfDNA screening results indicative of maternal neoplasm: survey of current practice and management needs.
Giles ME; Murphy L; Krstić N; Sullivan C; Hashmi SS; Stevens B
Prenat Diagn; 2017 Feb; 37(2):126-132. PubMed ID: 27878832
[TBL] [Abstract][Full Text] [Related]
27. Fetal aneuploidy detection by maternal plasma DNA sequencing: a technology assessment.
Walsh JM; Goldberg JD
Prenat Diagn; 2013 Jun; 33(6):514-20. PubMed ID: 23686655
[TBL] [Abstract][Full Text] [Related]
28. Antenatal noninvasive DNA testing: clinical experience and impact.
Ferres MA; Hui L; Bianchi DW
Am J Perinatol; 2014 Aug; 31(7):577-82. PubMed ID: 24683075
[TBL] [Abstract][Full Text] [Related]
29. Genome-wide copy number analysis on DNA from fetal cells isolated from the blood of pregnant women.
Kølvraa S; Singh R; Normand EA; Qdaisat S; van den Veyver IB; Jackson L; Hatt L; Schelde P; Uldbjerg N; Vestergaard EM; Zhao L; Chen R; Shaw CA; Breman AM; Beaudet AL
Prenat Diagn; 2016 Dec; 36(12):1127-1134. PubMed ID: 27761919
[TBL] [Abstract][Full Text] [Related]
30. Noninvasive Prenatal Genetic Testing: Current and Emerging Ethical, Legal, and Social Issues.
Minear MA; Alessi S; Allyse M; Michie M; Chandrasekharan S
Annu Rev Genomics Hum Genet; 2015; 16():369-98. PubMed ID: 26322648
[TBL] [Abstract][Full Text] [Related]
31. Genetic effects of a 13q31.1 microdeletion detected by noninvasive prenatal testing (NIPT).
Jia Y; Zhao H; Shi D; Peng W; Xie L; Wang W; Jiang F; Zhang H; Wang X
Int J Clin Exp Pathol; 2014; 7(10):7003-11. PubMed ID: 25400788
[TBL] [Abstract][Full Text] [Related]
32. Bioinformatics Pipeline for Accurate Quantification of Fetal DNA Fraction in Maternal Plasma.
Ni M; Peng XL; Jiang P
Methods Mol Biol; 2019; 1909():177-180. PubMed ID: 30580431
[TBL] [Abstract][Full Text] [Related]
33. Detection and prognostic value of recurrent exportin 1 mutations in tumor and cell-free circulating DNA of patients with classical Hodgkin lymphoma.
Camus V; Stamatoullas A; Mareschal S; Viailly PJ; Sarafan-Vasseur N; Bohers E; Dubois S; Picquenot JM; Ruminy P; Maingonnat C; Bertrand P; Cornic M; Tallon-Simon V; Becker S; Veresezan L; Frebourg T; Vera P; Bastard C; Tilly H; Jardin F
Haematologica; 2016 Sep; 101(9):1094-101. PubMed ID: 27479820
[TBL] [Abstract][Full Text] [Related]
34. Noninvasive prenatal screening and maternal malignancy: role of imaging.
Jha P; Lenaerts L; Vermeesch J; Norton M; Amant F; Glanc P; Poder L
Abdom Radiol (NY); 2023 May; 48(5):1590-1598. PubMed ID: 37095202
[TBL] [Abstract][Full Text] [Related]
35. Applications of genetic-epigenetic tissue mapping for plasma DNA in prenatal testing, transplantation and oncology.
Gai W; Zhou Z; Agbor-Enoh S; Fan X; Lian S; Jiang P; Cheng SH; Wong J; Chan SL; Jang MK; Yang Y; Liang RH; Chan WK; Ma ES; Leung TY; Chiu RW; Valantine H; Chan KA; Lo YD
Elife; 2021 Mar; 10():. PubMed ID: 33752803
[TBL] [Abstract][Full Text] [Related]
36. Noninvasive fetal genomic, methylomic, and transcriptomic analyses using maternal plasma and clinical implications.
Wong AI; Lo YM
Trends Mol Med; 2015 Feb; 21(2):98-108. PubMed ID: 25618775
[TBL] [Abstract][Full Text] [Related]
37. A microarray approach for systematic identification of placental-derived RNA markers in maternal plasma.
Tsui NB; Lo YM
Methods Mol Biol; 2008; 444():275-89. PubMed ID: 18425489
[TBL] [Abstract][Full Text] [Related]
38. Bioinformatics Approaches for Fetal DNA Fraction Estimation in Noninvasive Prenatal Testing.
Peng XL; Jiang P
Int J Mol Sci; 2017 Feb; 18(2):. PubMed ID: 28230760
[TBL] [Abstract][Full Text] [Related]
39. Implementation of whole genome massively parallel sequencing for noninvasive prenatal testing in laboratories.
Thung DT; Beulen L; Hehir-Kwa J; Faas BH
Expert Rev Mol Diagn; 2015 Jan; 15(1):111-24. PubMed ID: 25347354
[TBL] [Abstract][Full Text] [Related]
40. Cancer Diagnoses Following Abnormal Noninvasive Prenatal Testing: A Case Series, Literature Review, and Proposed Management Model.
Dow E; Freimund A; Smith K; Hicks RJ; Jurcevic P; Shackleton M; James PA; Fellowes A; Delatycki MB; Fawcett S; Flowers N; Pertile MD; McGillivray G; Mileshkin L
JCO Precis Oncol; 2021 Nov; 5():1001-1012. PubMed ID: 34994626
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
